Literature DB >> 15931331

Polycystic ovarian syndrome: diagnosis and management.

Michael T Sheehan1.   

Abstract

Polycystic ovarian syndrome (PCOS) affects 4% to 12% of women of reproductive age. The lack of well-defined diagnostic criteria makes identification of this common disease confusing to many clinicians. Also, with the varied manifestations of the disorder a patient may present to any one of several providers: an internist, family practitioner, nurse practitioner, pediatrician, gynecologist, dermatologist, or endocrinologist. Furthermore, the most distressing aspect of PCOS for any given patient may change over time, from hirsutism as a teenager to infertility as a young adult--potentially requiring several different providers along the way. It is important, therefore, that those caring for these patients understand not only the management issues pertinent to their specialty, but also appreciate the other potential health risks in these women. Recent insights into the pathophysiology of PCOS have shown insulin resistance to play a substantial role and as such have brought the long-term issues of type 2 diabetes mellitus and its resultant increased risk of coronary artery disease to the forefront. No longer can irregular menses and/or hirsutism be thought of as benign nuisances. This review will focus on the two most confusing aspects of PCOS for the practicing provider--diagnosis/differential diagnosis and treatment options. Special attention is given to the role of insulin resistance and the potential utility of insulin sensitizers in management. The benefit and utmost importance of lifestyle modification for the long-term health of these women is stressed as well. It is hoped that some clarity in this regard will allow more women to not only be diagnosed and managed properly for their presenting symptoms (hirsutism, irregular menses, etc.), but also to be educated and managed for the continuing health risk of insulin resistance throughout their lives.

Entities:  

Mesh:

Year:  2004        PMID: 15931331      PMCID: PMC1069067          DOI: 10.3121/cmr.2.1.13

Source DB:  PubMed          Journal:  Clin Med Res        ISSN: 1539-4182


  128 in total

1.  Comment on "Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome".

Authors:  M Ciampelli; A M Fulghesu; A Lanzone
Journal:  J Clin Endocrinol Metab       Date:  1999-08       Impact factor: 5.958

2.  Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome.

Authors:  C J Glueck; P Wang; R Fontaine; T Tracy; L Sieve-Smith
Journal:  Metabolism       Date:  1999-04       Impact factor: 8.694

3.  Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.

Authors:  D A Ehrmann; D J Schneider; B E Sobel; M K Cavaghan; J Imperial; R L Rosenfield; K S Polonsky
Journal:  J Clin Endocrinol Metab       Date:  1997-07       Impact factor: 5.958

4.  Anovulation after precocious pubarche: early markers and time course in adolescence.

Authors:  L Ibáñez; F de Zegher; N Potau
Journal:  J Clin Endocrinol Metab       Date:  1999-08       Impact factor: 5.958

5.  Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome.

Authors:  V De Leo; A la Marca; A Ditto; G Morgante; A Cianci
Journal:  Fertil Steril       Date:  1999-08       Impact factor: 7.329

6.  Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.

Authors:  D A Ehrmann; R B Barnes; R L Rosenfield; M K Cavaghan; J Imperial
Journal:  Diabetes Care       Date:  1999-01       Impact factor: 19.112

7.  Prevalence of attempting weight loss and strategies for controlling weight.

Authors:  M K Serdula; A H Mokdad; D F Williamson; D A Galuska; J M Mendlein; G W Heath
Journal:  JAMA       Date:  1999-10-13       Impact factor: 56.272

8.  Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome.

Authors:  M Ciampelli; A M Fulghesu; F Cucinelli; V Pavone; E Ronsisvalle; M Guido; A Caruso; A Lanzone
Journal:  Metabolism       Date:  1999-02       Impact factor: 8.694

9.  Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone.

Authors:  J Adams; S Franks; D W Polson; H D Mason; N Abdulwahid; M Tucker; D V Morris; J Price; H S Jacobs
Journal:  Lancet       Date:  1985 Dec 21-28       Impact factor: 79.321

10.  Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome.

Authors:  R A Wild; P C Painter; P B Coulson; K B Carruth; G B Ranney
Journal:  J Clin Endocrinol Metab       Date:  1985-11       Impact factor: 5.958

View more
  37 in total

1.  Effect of overweight/obesity on IVF-ET outcomes in chinese patients with polycystic ovary syndrome.

Authors:  Kai Huang; Xiuhua Liao; Xiyuan Dong; Hanwang Zhang
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Menstrual disorders and menstrual hygiene practices in higher secondary school girls.

Authors:  M K C Nair; D S Chacko; Manju Ranjith Darwin; K Padma; Babu George; Russell P S
Journal:  Indian J Pediatr       Date:  2011-05-28       Impact factor: 1.967

3.  Western-style diet, with and without chronic androgen treatment, alters the number, structure, and function of small antral follicles in ovaries of young adult monkeys.

Authors:  Cecily V Bishop; Fuhua Xu; Jing Xu; Alison Y Ting; Etienne Galbreath; Whitney K McGee; Mary B Zelinski; Jon D Hennebold; Judy L Cameron; Richard L Stouffer
Journal:  Fertil Steril       Date:  2015-12-21       Impact factor: 7.329

4.  Increased serum C-reactive protein levels in normal weight women with polycystic ovary syndrome.

Authors:  A Makedos; D G Goulis; M Arvanitidou; G Mintziori; A Papanikolaou; A Makedou; D Panidis
Journal:  Hippokratia       Date:  2011-10       Impact factor: 0.471

Review 5.  Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility.

Authors:  Dimitrios Panidis; Konstantinos Tziomalos; Efstathios Papadakis; Christos Vosnakis; Panagiotis Chatzis; Ilias Katsikis
Journal:  Endocrine       Date:  2013-04-27       Impact factor: 3.633

6.  Polycystic ovary syndrome, body mass index and outcomes of assisted reproductive technologies.

Authors:  Hind A Beydoun; Laurel Stadtmauer; May A Beydoun; Helena Russell; Yueqin Zhao; Sergio Oehninger
Journal:  Reprod Biomed Online       Date:  2009-06       Impact factor: 3.828

7.  Uncoupling protein 2 expression affects androgen synthesis in polycystic ovary syndrome.

Authors:  Yun Liu; Hong Jiang; Fu-Qi Xing; Wu-Jian Huang; Li-Hua Mao; Ling-Yun He
Journal:  Endocrine       Date:  2012-09-25       Impact factor: 3.633

Review 8.  The role of insulin-sensitizing agents in the treatment of polycystic ovary syndrome.

Authors:  Niki Katsiki; Eleni Georgiadou; Apostolos I Hatzitolios
Journal:  Drugs       Date:  2009-07-30       Impact factor: 9.546

9.  Diabetes mellitus, hypothalamic hypoestrogenemia, and coronary artery disease in premenopausal women (from the National Heart, Lung, and Blood Institute sponsored WISE study).

Authors:  Bina Ahmed; C Noel Bairey Merz; B Delia Johnson; Vera Bittner; Sarah L Berga; Glenn D Braunstein; T Keta Hodgson; Karen Smith; Leslee Shaw; Sheryl F Kelsey; George Sopko
Journal:  Am J Cardiol       Date:  2008-05-09       Impact factor: 2.778

10.  A modified ultra-long pituitary downregulation protocol improved endometrial receptivity and clinical outcome for infertile patients with polycystic ovarian syndrome.

Authors:  Fei Gong; Xihong Li; Shunji Zhang; Hainan Ma; Sufen Cai; Juan Li; G E Lin; Guangxiu Lu
Journal:  Exp Ther Med       Date:  2015-09-23       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.